Search details
1.
Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse.
Blood
; 140(17): 1907-1916, 2022 10 27.
Article
in English
| MEDLINE | ID: mdl-35789260
2.
Effectiveness of tixagevimab/cilgavimab in patients with hematological malignancies as a pre-exposure prophylaxis to prevent severe COVID-19: a Czech retrospective multicenter study.
Ann Hematol
; 103(3): 981-992, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-38092996
3.
Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic.
Ann Hematol
; 102(1): 107-115, 2023 Jan.
Article
in English
| MEDLINE | ID: mdl-36369497
4.
COVID-19 in patients with chronic lymphocytic leukemia: a multicenter analysis by the Czech CLL study group.
Ann Hematol
; 102(4): 811-817, 2023 Apr.
Article
in English
| MEDLINE | ID: mdl-36847805
5.
Circulating tumor DNA in Hodgkin lymphoma.
Ann Hematol
; 101(11): 2393-2403, 2022 Nov.
Article
in English
| MEDLINE | ID: mdl-36074181
6.
Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world.
Eur J Haematol
; 109(2): 162-165, 2022 Aug.
Article
in English
| MEDLINE | ID: mdl-35502609
7.
Burkitt lymphoma-a retrospective analysis of data from the Registry of the Czech Lymphoma Study Group with external validation of the Burkitt lymphoma International Prognostic Index.
Neoplasma
; 69(6): 1466-1473, 2022 Dec.
Article
in English
| MEDLINE | ID: mdl-36591807
8.
External validation of International Prognostic Score for asymptomatic early stage chronic lymphocytic leukaemia and proposal of an alternative score.
Br J Haematol
; 193(1): 133-137, 2021 04.
Article
in English
| MEDLINE | ID: mdl-33280081
9.
Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group.
Br J Haematol
; 193(4): 769-778, 2021 05.
Article
in English
| MEDLINE | ID: mdl-33618437
10.
Rituximab, Cyclophosphamide and Dexamethasone (RCD) Chemoimmunotherapy for Relapsed Chronic Lymphocytic Leukaemia.
Eur J Clin Invest
; 51(4): e13421, 2021 Apr.
Article
in English
| MEDLINE | ID: mdl-33022756
11.
miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels.
Blood
; 132(22): 2389-2400, 2018 11 29.
Article
in English
| MEDLINE | ID: mdl-30213873
12.
The interval between progression and therapy initiation is the key prognostic parameter in relapsing diffuse large B cell lymphoma: analysis from the Czech Lymphoma Study Group database (NIHIL).
Ann Hematol
; 99(7): 1583-1594, 2020 Jul.
Article
in English
| MEDLINE | ID: mdl-32506244
13.
First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients.
Ann Hematol
; 98(8): 1961-1972, 2019 Aug.
Article
in English
| MEDLINE | ID: mdl-31065733
14.
Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance.
Hematol Oncol
; 36(5): 773-778, 2018 Dec.
Article
in English
| MEDLINE | ID: mdl-30129045
15.
Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma.
Hematol Oncol
; 36(1): 110-115, 2018 Feb.
Article
in English
| MEDLINE | ID: mdl-29083050
16.
The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database.
Ann Hematol
; 97(4): 669-678, 2018 Apr.
Article
in English
| MEDLINE | ID: mdl-29318369
17.
Can Rituximab Improve the Outcome of Patients with Nodular Lymphocyte-Predominant Hodgkin's Lymphoma?
Acta Haematol
; 134(3): 187-92, 2015.
Article
in English
| MEDLINE | ID: mdl-26021284
18.
Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation.
Am J Hematol
; 94(2): E50-E53, 2019 02.
Article
in English
| MEDLINE | ID: mdl-30474171
19.
Cognitive impairment associated with Hodgkin's lymphoma and chemotherapy.
Neurosci Lett
; 797: 137082, 2023 02 16.
Article
in English
| MEDLINE | ID: mdl-36693557
20.
Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era.
Blood Adv
; 7(23): 7295-7303, 2023 12 12.
Article
in English
| MEDLINE | ID: mdl-37729621